Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 269.5% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, a growth of 269.5% from the September 15th total of 10,500 shares. Based on an average daily volume of 139,900 shares, the short-interest ratio is currently 0.3 days.

Astellas Pharma Stock Performance

Shares of Astellas Pharma stock opened at $11.71 on Friday. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $13.56. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average price of $11.93 and a 200-day moving average price of $10.72. The company has a market cap of $21.19 billion, a PE ratio of 167.29 and a beta of 0.37.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.24 EPS for the quarter. The business had revenue of $3.03 billion during the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. Equities analysts anticipate that Astellas Pharma will post 0.54 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.